Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 93552
The preclinical programs under this license include NUC-202, a targeted anti-cancer analog for the treatment of hepatocellular carcinoma; NUC-404, a targeted nucleotide analog for the treatment of hepatitis B; and NUC-101, a targeted nucleotide analog for the treatment of hepatitis C.
LTP is a promising technology platform developed by Licensor with applicability in a range of hepatic and hepatic-mediated indications. Given the increased focus on liver-related health by drug companies and the substantial medical need in China for liver-related medicines
IPSCIO Record ID: 10115
This technology effectively links anti-viral and anti-cancer drugs to purified hemoglobin, the starting material for Hemolink. The created hemoglobin-drug complex is then transported to the liver through the natural pathway for hemoglobin uptake and clearance from the blood plasma. This could allow for targeted delivery of anti-viral drugs to the liver in the case of patients suffering from Hepatitis C, and anti-cancer drugs in the case of patients with cancers of the liver. It is expected that at least two drug delivery compounds will move into preclinical development.
IPSCIO Record ID: 385607
Pradefovir is a prodrug that targets adefovir to the liver for the treatment of hepatitis B.
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection.
IPSCIO Record ID: 383572
Compound means an Agents prodrug that utilizes the Licensor Liver Targeting Prodrug Technology and is discovered or Developed by or for the account of a Party pursuant to such Partys performance of its obligations under this Agreement.
Agent means any of the following natural omega-3 fatty acids
— EPA (i.e., icosapentaenoic acid) or an EPA ester,
— DHA (i.e., docosahexaenoic acid) or a DHA ester,
— a combination of EPA (or an EPA ester) with DHA (or a DHA ester) or,
— any of the individual omega-3 fatty acids or a complex mixture of the omega-3 fatty acids contained (as of the Effective Date) within EpanovaTM.
Licensor Liver Targeting Prodrug Technology means Licensors program for the development of a liver-specific drug targeting technology for chemically modifying the molecule to render it inactive until the modification is cleaved off by a liver-specific enzyme, including all related intellectual property and other related rights of Licensor, and any and all related clinical and non-clinical data compiled by Licensor, in each case arising from the Licensors operation of such program.
The patents include
Prodrug compounds and uses for Liver Targeting;
Prodrug compounds and uses thereof; and,
Prodrug compounds and their uses thereof.